Genetic Determinants of Analgesic Responsiveness
Our findings support the relevance of CYP2D6, CYP2C19, and CYP2C9 as key pharmacogenes for PGx testing in chronic pain management. The results suggest that a genetic predisposition in CYP2D6 and COMT, associated with increased pain sensitivity, may contribute to insufficient analgesia and subsequent TF. These insights indicate the potential value of incorporating CYP2D6 and COMT as pain-modulating genetic markers into the broader framework of PGx testing.
Authors
- Isabell Seibert
- Florine M. Wiss (ORCID: https://orcid.org/0009-0001-3618-4679)
- Samuel Allemann (ORCID: https://orcid.org/0000-0003-4067-9401)
- Anna Bollinger (ORCID: https://orcid.org/0000-0003-4616-2534)
- Chiara Jeiziner (ORCID: https://orcid.org/0000-0002-1132-0240)
- Céline K. Stäuble (ORCID: https://orcid.org/0000-0002-2437-4803)
- Julia Gianora
- Isabelle O. Urdieux
- Henriette E. Meyer zu Schwabedissen
- Kurt E. Hersberger
- Tanja Schüpbach
Institutions
- University of Basel (CH)
- Solothurner Spitäler (CH)
- Stadtspital Waid (CH)
Publication Details
- Journal
- Clinical Journal of Pain
- Published
- 2026-01-12
- DOI
- https://doi.org/10.1097/ajp.0000000000001358
- Primary Topic
- Pharmacogenetics and Drug Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.00